SANEMUS supports a German biotech start-up in searching venture capital. With its innovative, patented compound, the company offers a completely new therapeutic approach for the treatment of HIV patients who are resistant to therapy. Initial talks with institutional VCs have already been started. If you are interested in participating, please contact us.